PPC
BCRX icon

Park Place Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Park Place Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-237
Closed -$1.2K – 861
2024
Q1 		$1.2K Buy
+237
New +$1.33K ﹤0.01% 873
2023
Q4 		– Sell
-112
Closed -$793 – 875
2023
Q3 		$793 Hold
112
– – ﹤0.01% 991
2023
Q2 		$788 Hold
112
– – ﹤0.01% 993
2023
Q1 		$934 Hold
112
– – ﹤0.01% 990
2022
Q4 		$1K Buy
+112
New +$1.4K ﹤0.01% 983

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Park Place Capital's BCRX Position: Q2 2024 in Review

Park Place Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 237 shares — an estimated $1.2K sold.

Park Place Capital first reported a position in BCRX in Q4 2022 and held it in 5 quarters. The position peaked at $1.2K in Q1 2024. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • Park Place Capital reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Park Place Capital sold 237 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $1.2K.
  • Park Place Capital first reported a position in BioCryst Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Park Place Capital's BioCryst Pharmaceuticals position peaked at $1.2K in Q1 2024.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Park Place Capital's 13F filing for Q2 2024, filed 2 Jul 2024.